Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. (EVH) on October 1, 2021. The report details the consummation of a previously announced merger transaction involving Vital Decisions Acquisition, LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the structural completion of a merger and the issuance of equity securities.
Material Changes
On October 1, 2021, EVH consummated the transactions under the Merger Agreement dated August 2, 2021. As a result of this closing:
- 1,771,219 shares of EVH Class A Common Stock were issued to Seller Parties who qualified as "accredited investors."
- The issuance was exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
- The issued shares are classified as restricted securities under Rule 144 and are subject to resale restrictions and holding period requirements.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risk factors beyond the standard regulatory disclosures regarding the restricted nature of the newly issued shares. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the total number of shares issued (1,771,219) and the identity of the Seller Parties receiving the equity.
- Confirm the restricted status of the issued shares and the applicable holding periods under Rule 144.
- Review the full Merger Agreement dated August 2, 2021, for details on the consideration paid to non-accredited investors or other transaction terms not detailed in this 8-K.
- Check subsequent filings for the impact of this transaction on the company's capitalization table and diluted share count.